No. 20-1258
Ono Pharmaceutical Co., Ltd., et al. v. Dana-Farber Cancer Institute, Inc.
Tags: conception conception-standard federal-circuit-rule inventorship-correction joint-inventorship non-obviousness novelty patent-law prior-art
Latest Conference:
2021-05-20
Question Presented (from Petition)
Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are "not probative" of whether those alleged contributions were significant to conception.
Question Presented (AI Summary)
Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are 'not probative' of whether those alleged contributions were significant to conception
Docket Entries
2021-05-24
Petition DENIED. Justice Breyer took no part in the consideration or decision of this petition.
2021-05-04
DISTRIBUTED for Conference of 5/20/2021.
2021-05-03
Reply of petitioners Ono Pharmaceutical Co., Ltd.,, et al. filed. (Distributed)
2021-04-20
Brief of respondent Dana-Farber Cancer Institute, Inc. in opposition filed.
2021-04-07
Motion to extend the time to file a response is granted and the time is extended to and including April 20, 2021.
2021-04-05
Motion to extend the time to file a response from April 12, 2021 to April 20, 2021, submitted to The Clerk.
2021-03-08
Petition for a writ of certiorari filed. (Response due April 12, 2021)
Attorneys
Dana-Farber Cancer Institute, Inc.
Donald R. Ware — Foley Hoag LLP, Respondent
Ono Pharmaceutical Co., Ltd.,, et al.
Seth P. Waxman — Wilmer Cutler Pickering Hale and Dorr LLP, Petitioner